Related Experiment Videos
Structure-antimutagenic activity relationship study of plicatin B
S R Menon1, V K Patel, L A Mitscher
1Department of Medicinal Chemistry and Department of Microbiology, University of Kansas, Lawrence, Kansas 66045, USA.
Journal of Natural Products
|January 23, 1999
Summary
Plicatin B, an antimutagenic compound, was studied to understand its action. A modified analogue showed reduced toxicity and increased effectiveness, suggesting its mode of action does not involve a Michael acceptor mechanism.
Area of Science:
- Natural Product Chemistry
- Medicinal Chemistry
- Toxicology
Background:
- Plicatin B is an antimutagenic compound isolated from Psoralea juncea.
- Understanding the structure-activity relationship (SAR) is crucial for optimizing antimutagenic properties.
- Elucidating the chemical mode of action can guide the development of novel antimutagens.
Purpose of the Study:
- To conduct a systematic SAR study of plicatin B and its analogues.
- To investigate the antimutagenic activity against ethyl methanesulfonate-induced mutations.
- To explore the role of the alpha,beta-unsaturated carbonyl moiety in antimutagenicity.
Main Methods:
- Synthesis of plicatin B analogues, including a dihydro derivative.
- Utilizing the modified Ames test protocol with Salmonella typhimurium strain TA100.
- Assessing antimutagenic activity and cytotoxicity of tested compounds.
Main Results:
- The dihydro analogue (3) exhibited reduced cytotoxicity compared to plicatin B (1).
- Compound 3 demonstrated enhanced antimutagenic efficacy relative to the parent compound.
- These findings preliminarily exclude a Michael acceptor role for the unsaturated carbonyl group.
Conclusions:
- The SAR study provides insights into the chemical basis of plicatin B's antimutagenic activity.
- Saturation of the alkene double bond improves the therapeutic potential by reducing toxicity.
- The mechanism of action appears independent of a Michael acceptor interaction.